News
On the Occasion of Its General Meeting, France Biotech Confirms Its Unifying Mission for All Innovative Small and Medium-Sized Life-Science Businesses in Its Statutes
PARIS-(Business Wire)-July 2, 2008 - Following its Annual General Meeting, held on Tuesday 24th June, in Paris, France Biotech, the French life sciences industry association (www.france-biotech.org), reappointed its Board of Directors according to the statutes of association.
France Biotech also called an extraordinary general meeting on this occasion to amend its statutes of association, so that innovative life science companies could be widely represented, and to ensure an optimal take-up with the association:
- The board of directors must choose from among its members a chairman and two vice-chairmen who must have significant experience as entrepreneurs in life sciences;
- One of the two vice-chairmen will have the responsibility of taking over the chair when the mandate of the out-going chairman expires;
- Three seats on the board of directors will, if possible, be reserved for members in the medical devices and diagnostic technology sectors, and other Life Science sectors.
"France Biotech has today put in place a dynamic and unifying network which is working to improve the ecosystem of innovative small and medium-sized Life Science and advanced technology businesses, so that tomorrow's leaders may emerge", says Dr Philippe Pouletty, chairman of France Biotech.
The out-going board member, Gilles Avenard, co-founder of BioAlliance Pharma, "specialty pharma" specialized in opportunistic infections, cancer and AIDS has been re-elected unanimously and two new board members are taking their seats on France Biotech's board of directors : Salman Al-Mahmood, Scientific Director and co-founder of Gene Signal, a research and development company for therapeutic solutions based on angiogenesis mechanisms; and Loic Maurel, the new CEO of ExonHit Therapeutics, a leading company in the field of alternative DNA splicing, listed on the Alternext market of NYSE Euronext since 2005. Composition of the Board of Directors of France Biotech
Chairman - Dr Philippe Pouletty, chairman of Wittycell and Deinove, General Partner of Truffle Capital
The two vice-chairmen will be appointed at the next Board Meeting in September
Members of the new Board of Directors
Salman Al-Mahmood (Gene Signal)
Pascale Altier (Institut Pasteur)
Gilles Avenard (Bioalliance Pharma)
Philippe Berthon (Aurgalys)
Herve Brailly (Innate Pharma)
Andre Choulika (Cellectis)
Lison Chouraki (Auditor)
Philippe Cramer (MCL)
Herve Duchesne de Lamotte (IDM)
Veronique Dufey (Ifremer)
Michel Finance (Entrepreneur)
Michel Kaczorek (Serenitude Biotech)
Anne-Marie Masquelier (Genethon)
Loic Maurel (ExonHit Therapeutics -Alternext of NYSE Euronext Paris - ISIN: FR0004054427)
Christian Policard (Biotech Development Consultant)
Jean-Christophe Renondin (CDC Innovation)
Honorary chairman, permanent member of the Board of Directors - Pascal Brandys (Biobank)
About France Biotech
France Biotech (www.france-biotech.org) is the French association of life science industry and their partners. Its mission is to help to raise the French biotechnology industry to the position of European leader. France Biotech is a driving force for change, which lobbies public authorities, economic organisations, academic research, the media and particularly the investors' community, to encourage the emergence of biotechnology as a priority high-tech industry, and to improve the economic, legal, regulatory and managerial environment of these businesses.
France Biotech today has 150 members.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
